Appendices
- Appendix 1: Acknowledgements
- Appendix 3: Regional differences in indicators of health, determinants and prevention
- Appendix 4: Summary of key epidemiological data
- Appendix 5: Detailed international comparisons
- Appendix 6: References to websites providing background information
29 May 2007
This report has been a joint effort of many. The Supervisory committee of the Ministry of Health Welfare and Sports and the National Scientific Advisory Committee for this PHSF have greatly contributed to the potential policy relevance and the scientific basis of this PHSF report, respectively. The finalization of the report was a joint effort by the PHSF projectteam. Many others contributed as well. PHSF supervisory committee of the Ministry of Health, Welfare and Sport Chairman H.H.P. Meijer Secretary Ir. S.I. Rutz (until February 2006) I. Storm, MSc Members Represenatives from various Directorates of the Ministry of Health, Wellfare and Sport and from Public Health Inspectorates Ir. J.A. Cornelese; Dr. J. Geelhoed; T.H. Halbertsma; Dr. J.W. Hartgerink; H.E.M. Hollenberg- van Pelt, MSc; M. Holling, MSc; J.R.C. Janse, MSc ; A.B.A. Kemper, MSc; L. Kootstra, MSc; M. van der Maten; J.K. van Wijngarden, MD; A.J.M Zengerink, MSc Representatives from the RIVM: Dr. A.E.M. de Hollander; Prof. dr. ing. J.A.M. van Oers; Dr. H. Verkleij National Scientific Advisory Committee Chairman Dr. M.J.W. Sprenger Members Prof. dr. J.M. Bensing; Dr. D. Bakker; R.J. Beuse, MSc (until May 2005); Dr. A. Boer; Prof. Dr. M.C.H. Donker; Dr. A.J.J. Voorham; Prof. Dr. T.E.D. van der Grinten; Prof. Dr. N.S. Klazinga; Prof. Dr. J.A. Knottnerus; Prof. dr. J.P. Mackenbach; Dr. G.R.M. Molleman; W.M.L.C.M. Schellekens, MSc; Prof. dr. J.L. Severens; Prof. dr. P. Schnabel; Dr. R. Bijl; Prof. dr. S.P. Verloove-Vanhorick; Dr. S. Buitendijk Observers on account of the PHSF project team: A. van den Berg Jeths, MSc (until November 2005); Dr. N. Hoeymans; Dr. A.E.M de Hollander; Ir. J.M. Melse; Prof. dr. ing. J.A.M. van Oers; Dr. J.J. Polder PHSF Project team Project leader and final editor Dr. A.E.M de Hollander Editing team Dr. N. Hoeymans; Ir. J.M. Melse; Prof. dr. ing. J.A.M. van Oers; Dr. J.J. Polder Members project team and authors Dr. P.W. Achterberg; A. van den Berg Jeths, MSc (until November 2005); Dr. P.G.N. Kramers; L.A.T.M. van Leest, MSc; Dr. F. van der Lucht; Ir. A.H.P. Luijben; Dr. ir. A.J. Schuit; Dr. H.F. Treurniet; Ir. K.E. Witte; S.L.N. Zwakhals, MSc Project support Ir. A.H.P. Luijben (project leader); C.L.C. Aarts MSc; A.J. Berends; S.W. Bongers, MSc; J. de Bruin, MSc; Ing. H. Giesbers, MSc; B. Kostalova, MSc; M.J.C. Middelburg; S. Rosbergen, MSc; Sanderse C; E. Slichter; Fidder & Löhr bv: K. van Daalen, W. van Hees English translation Taalcentrum-VU, Amsterdam; Dr. P. Bol Others involved Many other Dutch experts and institutions have contributed to the PHSF report. Their names and affiliations are provided on the website of this report (www.rivm.nl/vtv/phsf2006). |
29 May 2007
Table A3.1: Regional differences in indicators of health, determinants and prevention
|
29 May 2007
Table A8.1 gives the annual incidences and annual prevalences for the diseases selected for the PHSF. The data originate from GPs’ records and other care data registration schemes. Use has been made of data for 2003 or an average for several years. Where no recent data were available, older figures have been used (see notes). The figures have been standardized for the population as it was in 2003. The incidence data for acute illnesses relate to numbers of cases; therefore a given individual may feature several times. The incidence data for sub-acute and chronic disorders relate to numbers of individuals. Prevalence and incidence figures in excess of 2,500 have been rounded off to the nearest hundred; figures smaller than 2,500 to the nearest ten. For more detailed information concerning the tabulated data, please refer to the National Compass on Public Health (www.nationaalkompas.nl). The statistics in the table are not directly comparable with those presented in the PHSF 2002. In a number of cases, different sources have been used, or different decisions made regarding the variable to be reported. For the cancers, for example, the ten-year prevalences are reported, whereas in the PHSF 2002, the lifetime prevalences were reported. With regard to trends over time, the reader is referred to the information on the individual illnesses in the Compass, or to subsection 2.1, where the most important incidence, prevalence and mortality trends are summarized. In contrast to the PHSF 2002, we have not on this occasion presented a separate table of epidemiological study data. This is partly because no such data are available for most of the PHSF diseases , and partly because those epidemiological study data that are available for individual illness are mostly somewhat dated. Table A8.1: Annual incidence, annual prevalence (both on the basis of care records), mortality and lost life-years, standardized for the population of the Netherlands in 2003 (absolute numbers); sources as specified in the table
Used data sources:
Notes:
|
30 January 2008
For each indicator, a table is presented below listing the five EU member states with the best scores for the indicator in question and the five with the worst scores; where available, the averages for the fifteen old member states (EU-15) and the twenty-five current member states (EU-25) are given in the middle of the table. In cases where the Netherlands is neither in the five best-scoring member states, nor in the five worst scoring member states, the Dutch average is also given in the centre group of figures. In some cases, the figure given for the Netherlands differs from that quoted elsewhere in the PHSF. This is because the international comparisons have sometimes been made on the basis of other data sources, or because the (mortality) statistics have been standardized. |
Health Status
Table 1: Incidence of lung cancer (per 100,000), 2001 (Source: WHO-HFA, 2006)
| Table 2: Mortality attributable to lung cancer (per 100,000), 2002 (Source: WHO-HFA, 2006)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 3: Incidence of breast cancer (per 100,000), 2001 (Source: WHO-HFA, 2006)
| Table 4: Mortality attributable to breast cancer (per 100,000), 2002 (Source: WHO-HFA, 2006)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 5: Incidence of cervical cancer (per 100,000), 2001 (Source: WHO-HFA, 2006)
| Table 6: Mortality attributable to cancer (per 100,000), 2001 (Source: Eurostat, 2006)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 7: Healthy life expectancy, 2003 (Source: WHO, 2005a)
| Table 8a: Life expectancy at birth (women), 2003 (Source: Eurostat, 2006)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 8b: Life expectancy at birth (men), 2003 (Source: Eurostat, 2006)
| Table 9: Total mortality (per 100,000), 2001(Source: Eurostat, 2006)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 10: Infant mortality (per 1,000), 2003 (Source: Eurostat, 2006) Erratum: Per 100,000 in PHSF 2006 (p 315) should be per 1,000 infants.
| Table 11: Mortality attributable to coronary heart disease (per 100,000), 2001 (Source: Eurostat, 2006)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 12: Mortality attributable to stroke (per 100,000), 2001 (Source: WHO-HFA, 2006)
| Table 13: Mortality attributable to suicide (per 100,000), 2001 (Source: Eurostat, 2006)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 14: Mortality attributable to road traffic accidents (per 100,000), 2001 (Source: WHO-HFA, 2006)
| Table 15: Mortality attributable to chronic liver disease (per 100,000), 2001 (Source: WHO-HFA, 2006)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 16: Incidence of AIDS (per million), 2004 (Source: EuroHIV, 2005)
| Table 17: Percentage of people with serious ADL disabilities, 2001 (Source: Eurostat, 2006 )
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 18: Percentage of people in ‘good’ perceived health, 2004 (Source: Eurostat, 2006)
| ||||||||||||||||||||||||||
Determinants and prevention
Table 19: Percentage of infants still exclusively or partially breastfed at six months (Source: WHO-HFA, 2006)
| Table 20: Percentage of the population (>15 years) who are daily smokers (Source: WHO-HFA, 2006)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 21: Percentage of fifteen and sixteen-year-olds who have smoked in the last thirty days, 2003 (Source: Hibell et al., 2004; ESPAD study)
| Table 22: Alcohol consumption (litres of pure alcohol per person), 2003 (Source: WHO-HFA, 2006)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 23: Percentage of fifteen and sixteen-year-olds who have had three or more ‘drinking binges’ in the last months, 2003 (Source: Hibell et al., 2004; ESPAD study)
| Table 24: Number of problem drug users a per 1,000 people aged fifteen to sixty-four (Source: EMCDDA, 2005b)
a EMCDDA definition of problem use: intravenous drug use or prolonged/regular use of opiates, cocaine and/or amphetamines. Age band: fifteen to sixty-four. Methods may differ from country to country. Where more than one estimate was available for a country, the average was taken. | |||||||||||||||||||||||||||||||||||||||||||||||||
Table 25: Percentage of fifteen-year-olds who used contraception when they last had sexual intercourse; unweighted average for boys and girls, 2001/2002 (Source: Currie et al., 2004; HBSC)
| Table 26: Percentage of people who engage in moderate physical activity four to seven days per week, 2002 (Source: EORG, 2003a)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 27: Percentage of people who are overweight (BMI 25.0-29.9); unweighted average for men and women (Source: IOTF Prevalence Data, 2005)a
a The Netherlands has not been given a 'traffic light' colour, because it is on the boundary of amber and green. | Table 28: Percentage of people who are obese (BMI ≥ 30.0); unweighted average for men and women (Source: IOTF Prevalence Data, 2005)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 29: Percentage of children who are overweight or obese; unweighted average for boys and girls (Source: IOTF Prevalence Data, 2005)
| Table 30: Percentage of people with ample social support, 2002 (Source: EORG, 2003b)
| |||||||||||||||||||||||||||||||||||||||||||||||||
Table 31: Relative five-year survival rate for cancer (all forms, collectively), diagnosis 1990-1994 (Source: Sant et al., 2003a)
| Table 32: Relative five-year survival rate for breast cancer, diagnosis 1990-1994 (Source: Sant et al., 2003a)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 33: Relative five-year survival rate for lung cancer, diagnosis 1990-1994 (Source: Sant et al., 2003a)
| Table 34: Relative five-year survival rate for cervical cancer, diagnosis 1990-1994 (Source: Sant et al., 2003a)
| |||||||||||||||||||||||||||||||||||||||||||||||||
Table 35: Antibiotic resistance (MRSA percentage), 2004 (Source: EARSS, 2006)
| Table 36: Percentage of children vaccinated against measles, 2004 (Source: WHO-HFA, 2006)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 37: Breast cancer screening (percentage women attending for mammography in a given year), 2002 (Source: EORG, 2003c)
| ||||||||||||||||||||||||||||||
30 January 2008
Literature and data sources
|
|
| ||||||||||||||||
|
Literature
Data sources
| |||||||||||||||||
;){kind=link}
;){kind=link}
;){kind=link}
;){kind=link}
;){kind=link}
;){kind=link}
 and the Pompidou Group at the Council of Europe, 2004</p>
','../images/reference_1.gif');){kind=link}
;){kind=link}
;){kind=link}
 study: international report from the 2001/2002 survey. Kopenhagen: WHO Regional Office for Europe, 2004.</p>
','../images/reference_1.gif');){kind=link}
.</p>
','../images/reference_1.gif');){kind=link}
;){kind=link}
;){kind=link}
. Brussel: Europese Commissie, 2003b</p>
','../images/reference_1.gif');){kind=link}
: v61-118.</p>
','../images/reference_1.gif');){kind=link}
;){kind=link}
;){kind=link}